A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 30, 2009

Primary Completion Date

January 12, 2017

Study Completion Date

January 12, 2017

Conditions
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Interventions
BIOLOGICAL

Romiplostim

Administered by subcutaneous injection once a week.

Trial Locations (31)

2031

Research Site, Randwick

3052

Research Site, Parkville

4101

Research Site, South Brisbane

10016

Research Site, New York

10021

Research Site, New York

15224

Research Site, Pittsburgh

20010

Research Site, Washington D.C.

30322

Research Site, Atlanta

37232

Research Site, Nashville

40202

Research Site, Louisville

43205

Research Site, Columbus

45229

Research Site, Cincinnati

46260

Research Site, Indianapolis

48201

Research Site, Detroit

52242

Research Site, Iowa City

60611

Research Site, Chicago

61615

Research Site, Peoria

64108

Research Site, Kansas City

68114

Research Site, Omaha

70118

Research Site, New Orleans

75390

Research Site, Dallas

76104

Research Site, Fort Worth

77030

Research Site, Houston

89109

Research Site, Las Vegas

92123

Research Site, San Diego

92868

Research Site, Orange

08901

Research Site, New Brunswick

M5G 1X8

Research Site, Toronto

H3T 1C5

Research Site, Montreal

H4A 3J1

Research Site, Montreal

08035

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY